Patents by Inventor Malini Sen

Malini Sen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
    Patent number: 7713526
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: May 11, 2010
    Assignee: The Regents of the University of California
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
    Patent number: 7682607
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: March 23, 2010
    Assignee: The Regents of the University of California
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
    Publication number: 20040203003
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Application
    Filed: March 5, 2004
    Publication date: October 14, 2004
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M Leoni, Maripat Corr, Dennis A Carson
  • Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
    Publication number: 20030165500
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Application
    Filed: November 1, 2002
    Publication date: September 4, 2003
    Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
    Publication number: 20030044409
    Abstract: This invention is in the field of immunology. More specifically, it relates to compositions and methods for identifying, treating and preventing cancer by targeting the extracellular domains of the frizzled receptor family of proteins.
    Type: Application
    Filed: May 1, 2001
    Publication date: March 6, 2003
    Inventors: Dennis A. Carson, Maripat Corr, Chae-Seo Rhee, Lorenzo M. Leoni, Malini Sen